Back to Ask the Diabetes Team Ask the Diabetes Team

From Inver Grove Heights, Minnesota, USA:

My 20-year-old daughter has been pumping Humalog for about eight and a half years. Last week, the mail order pharmacy contacted us and explained that I would either need to switch from Humalog to NovoLog or transfer her prescription to a local pharmacy due to the rising cost of Humalog and that my insurance would no longer cover the cost of it through them. I don't have much information about NovoLog and didn't know if it was going to be a huge change for her. My daughter is due to go to the clinic next month, so I will have her ask the doctor then, but was just looking for a bit of information.


Please review our previous questions about Insulin Analogs. In general, the rapid-acting insulins lispro (Humalog), aspart (NovoLog), and glulisine (Apidra), while slightly different in their exact amino acid sequence make up, are very similar in clinical effect. Your daughter should likely not note any difference. Anecdotally, I have had patients who were on Humalog and switched to NovoLog and found that their insertion sites lasted a little longer, were a little less irritated, and that the effect of the insulin lasted perhaps slightly longer.


Original posting 24 Sep 2008
Posted to Insulin Analogs


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: Tuesday April 06, 2010 15:10:16
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.